Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05210283 · ClinicalTrials.gov registry record
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
A clinical trial of Colorectal Cancer, sponsored by Exact Sciences Corporation.
- Active
- Registry status
- 1,017
- Enrollment target
- 20
- Study locations
NCT05210283: Active study of Colorectal Cancer, sponsored by Exact Sciences Corporation.
NCT05210283 is a study of Colorectal Cancer that is active but no longer recruiting, run by Exact Sciences Corporation. The registered enrollment target is 1,017 participants, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05210283, a study of Colorectal Cancer, is active but no longer recruiting, sponsored by Exact Sciences Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 1,017 participants
- Enrollment target
- 20
- Study locations
Study Summary
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.
Conditions Studied
Interventions
- DEVICE MRD
Study Locations (20)
Florida
- University of Florida Division of Hematology & Oncology - Gainesville
- Mount Sinai Medical - Comprehensive Cancer Center - Miami Beach
- Mid Florida Cancer Centers - Orange City
Maryland
- MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital - Baltimore
- Meritus Center for Clinical Research - Hagerstown
- University of Maryland St. Joseph Medical Center - Towson
North Carolina
- Atrium Health Levine Cancer Institute - Charlotte
- FirstHealth Outpatient Cancer Center - Pinehurst
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
California
- Facey Medical Group - Mission Hills - Endoscopy Center & Gastroenterology - Mission Hills
- Torrance Memorial Hunt Cancer Institute - Torrance
Illinois
- Edward Cancer Center - Elmhurst
- Illinois Cancer Care - Peoria
Iowa
- Mercy Medical Center - Cedar Rapids
Kansas
- University of Kansas Cancer Center - Westwood
Minnesota
- Metro Minnesota Community Oncology Consortium (MMCORC) - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,017 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2027-05-15 |
What the registry record for NCT05210283 still lists
NCT05210283 is an observational study that tracks outcomes without assigning an intervention. Its 1,017 participants enrollment target places it among the larger protocols in the corpus, below the 1,542-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRD is the first listed.
NCT05210283 names 20 study sites across 12 states, led by Florida, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05210283 about?
NCT05210283 is a clinical study titled "CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer". The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up ...
What is the current status of trial NCT05210283?
This trial is currently active not recruiting. The enrollment target is 1,017 participants. The study started on 2021-12-15. Estimated completion is 2027-05-15.
What conditions does trial NCT05210283 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT05210283?
The interventions under investigation include: MRD (DEVICE).
Who is sponsoring clinical trial NCT05210283?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05210283 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05210283's enrollment target sits among peer trials
1,017 46th of 381 higher than 336 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI